An independent Corporate Reputation Survey of Pharma Companies, including 800 patient groups in 43 countries worldwide, ranked Menarini amongst the world’s top ten Pharmaceutical companies closest to patients’ needs.

MENARINI CLIMBS UP THE RANKING TO BE AMONGST TOP TEN COMPANIES CONSIDERED THE MOST "PATIENT FRIENDLY"

Being close to one’s patients is a quality that cannot be measured in terms of turnover or size and even a company like Menarini can come close or even exceed the level of Big Pharma, just like David and Goliath. Menarini, 37th out of 19,042 companies in the worldwide ranking in terms of turnover, was awarded 4th place for its patient-centric strategies and for acting with integrity and 6th place for the high quality information it provides to patients. This is the outcome of an independent study conducted on 800 patient groups by PatientView, a UK-based research company which works closely with patient groups in order to give them voice, and which resulted in a ranking of the world’s most ‘patient friendly’ pharmaceutical companies. According to the outcome of the 2013 Corporate Reputation survey, which included patient groups from 43 countries worldwide, Menarini ranked high amongst the world’s “top ten” Pharma companies regarded as closest to patients’ needs. It was also considered one of the three companies who stood out as “Rising Stars”, with a significant upward shift in the overall, worldwide ranking compared to last year’s ranking. In the global ranking Menarini jumped 11 places from 19th to 8th position, overtaking some of the world’s most renowned Pharma companies such as ViiV, Gilead, AbbVie, Pfizer, Janssen, Roche, and Eli Lilly, surprisingly leaving some of the larger Big Pharma multinationals behind them.   The six performance indicators PatientView adopted for the survey were patient centricity, quality of information provided, record on patient safety, usefulness of products to patients, record of transparency towards patients and consumers, and acting with integrity.   Menarini ranked high in all the categories thanks to a number of patient-oriented initiatives, such as a toll free number made voluntarily available to patients through which they may consult physicians and seek assistance in relation to a number of different medical conditions, the opportunity to pose anonymous questions to experts and consultants through the company’s website, and the introduction of “patient cards”  which accompany the patient leaflets and provide further information on both the therapy and medicines which might interact with the product in question. “We are proud of the results attained by Menarini as far as our reputation with patients is concerned as this is tangible recognition of our mission to purvey the highest possible quality drugs and services” – commented the Chairman of The Menarini Group, Lucia Aleotti – “patients are at the centre of what we do and must be increasingly informed, knowledgeable, and responsible.”